# Efficacy and Safety of Morning Versus Evening Intake of Simvast Controlled Release (CR) Tablet in Patients With Hyperlipidemia

> **NCT00973115** · PHASE3 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 132 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** Simvastatin CR

## Key facts

- **NCT ID:** NCT00973115
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2016-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00973115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00973115, "Efficacy and Safety of Morning Versus Evening Intake of Simvast Controlled Release (CR) Tablet in Patients With Hyperlipidemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00973115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*